CAL-056 is under clinical development by Calgent Biotechnology and currently in Phase I for Multiple Myeloma (Kahler Disease). According to GlobalData, Phase I drugs for Multiple Myeloma (Kahler Disease) have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CAL-056’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CAL-056 mesylate is under development for the treatment of resistant or refractory solid tumors, colon cancer, pancreatic cancer, colorectal cancer, lung cancer, breast cancer, bladder cancer and lymphoma, acute myelocytic leukemia (AML, acute myeloblastic leukemia), multiple myeloma (Kahler disease) and lung disease (lung fibrosis), unspecified ophthalmological disorders, osteoarthritis, rheumatoid arthritis. It is administered through oral route. The drug candidate acts by targeting ITCH E3 ubiquitin ligase.
For a complete picture of CAL-056’s drug-specific PTSR and LoA scores, buy the report here.